Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up

BMJ

Volumn 314, Issue 7076, 1997, Pages 266-

  Mcshane, Rupert ^a   Keene, Janet ^a   Gedling, Kathy ^a   Fairburn, Christopher ^a   Jacoby, Robin ^a   Hope, Tony ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PROMAZINE; THIORIDAZINE;

AGED; AGGRESSION; ARTICLE; AUTOPSY; BEHAVIOR DISORDER; CIRCADIAN RHYTHM; COGNITIVE DEFECT; DEMENTIA; FEMALE; HUMAN; INTERVIEW; LEWY BODY; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTIPSYCHOTIC AGENTS; AUTOPSY; COGNITION DISORDERS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; PARKINSON DISEASE, SECONDARY; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 0031014243     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.314.7076.266     Document Type: Article

References (43)

1. Devanand DP, Sackeim HA, Mayeux R. Psychosis, behavioral disturbance, and the use of neuroleptics in dementia. Compr Psychiatry 1988; 29: 387–401.
2. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63.
3. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992; 86: 138–45.
4. Schneider LS, Sobin PB. Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia. Psychopharmacol Bull 1992; 28: 71–79.
5. Smith DA, Perry PJ. Non-neuroleptic treatment of disruptive behavior in organic mental syndromes. Ann Pharmacother 1992; 26: 1400–1408.
6. Mann AH, Jenkins R, Cross PS, Gurland BJ. A comparison of the prescriptions received by the elderly in long-term care in New York and London. Psychol Med 1984; 14: 891–897.
7. Gilleard CJ, Morgan K, Wade BE. Patterns of neuroleptic use among the institutionalised elderly. Acta Psychiatr Scand 1983; 68: 419–25.
8. Elon R, Pawlson LG. The impact of OBRA on medical practice within nursing facilities. J Am Geriatr Soc 1992; 40: 958–63.
9. McGrath AM, Jackson GA. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. BMJ 1996; 312: 611–612.
10. Gotestam KG, Ljunghall S, Olsson B. A double-blind comparison of the effects of haloperidol and cis(Z)-clopenthixol in senile dementia. Acta Psychiatr Scand Suppl 1981; 294: 46–53.
11. Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1962; 10: 140–147.
12. Barton R, Hurst L. Unnecessary use of tranquillisers in elderly patients. Br J Psychiatry 1966; 112: 2036–42.
13. Davie JW, Blumenthal MD, Robinson Hawkins S. A model of risk of falling for psychogeriatric patients. Arch Gen Psychiatry 1981; 38: 463–467.
14. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–369.
15. Brown JW, Chobor A, Zinn F. Dementia testing in the elderly. J Nerv Ment Dis 1993; 181: 695–698.
16. Cowley LM, Glen RS. Double-blind study of thioridazine and haloperidol in geriatric patients with a psychosis associated with organic brain syndrome. J Clin Psychiatry 1979; 40: 411–419.
17. Barnes R, Veith R, Okimoto J, Raskind M, Gumbrecht G. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139: 1170–1174.
18. Sugarman AA, Williams H, Alderstein AM. Haloperidol in psychiatric disorders of old age. Am J Psychiatry 1964; 120: 1190–1192.
19. Tobin JM, Brousseau ER, Lorenz AA. Clinical evaluation of haloperidol in geriatric patients. Geriatrics 1970; 25: 119–22.
20. Smith GR, Taylor CW, Linkous P. Haloperidol versus thioridazine for the treatment of psychogeriatric patients: a double-blind clinical trial. Psychosomatics 1974; 15: 134–138.
21. Lehmann HE, Ban TA. Comparative pharmacotherapy of the aging psychotic patient Laval Med 1967; 38: 588–95.
22. Rosen JH. Double-blind comparison of haloperidol and thioridazine in geriatric outpatients. J Clin Psychiatry 1979; 40: 17–20.
23. Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46: 854–857.
24. Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the predictors study. Neurology 1994; 44: 2300–2307.
25. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type. Evidence of subgroups. Neurology 1985; 35: 453–61.
26. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989; 25: 39–48.
27. Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 1991; 29: 224–32.
28. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception Br J Psychiatry 1990; 157: 76–81.
29. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994; 51: 676–81.
30. Förstl H, Besthorn C, Geiger-Kabisch C, Sattel H, Scheiter-Gasser U. Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerised tomography findings. Acta Psychiatr Scand 1993; 87: 395–399.
31. Mortimer JA, Ebbitt B, Jun S, Finch M. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992; 42: 1689–96.
32. Hope T, Fairburn CG. The present behavioural examination (PBE): the development of an interview to measure current behavioural abnormalities. Psychol Med 1992; 22: 223–30.
33. Wilcock GK, Hope RA, Brooks DN, Lantos PL, Oppenheimer C, Reynolds GP, et al. Recommended minimum data to be collected in research studies on Alzheimer's disease. J Neurol Neurosurg Psychiatry 1989; 52: 693–700.
34. Foster P. Neuroleptic equivalence. Pharm J 1989;243;431–2.
35. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673–678.
36. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51: 888–95.
37. Drachman DA, Leavitt JB. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974; 30: 113–21.
38. Jellinger K. Neuropathologic findings after neuroleptic long-term therapy. In: Roizin L, Shiraki H, Grcevic N, eds. Neurotoxicology. New York: Raven Press, 1977: 25–42.
39. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, et al Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151: 1430–1436.
40. Figiel GS, Krishnan KR, Doraiswamy PM, Nemeroff CB. Caudate hyperintensities in elderly depressed patients with neuroleptic-induced parkinsonism. J Geriatr Psychiatry Neurol 1991; 4: 86–89.
41. Wisniewski HM, Constantinidis J, Wegiel J, Bobinski M, Tarnawski M. Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics. Alzheimer Dis Assoc Disord 1994; 8: 211–27.
42. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 1996; 66: 1592–1598.
43. Esiri MM. The basis for behavioural disturbances in dementia. J Neurol Neurosurg Psychiatry 1996; 61: 127–30.